← Humana overview

Humana vs Oscar Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Humana Inc (HUM)

Latest
▲3▼1

Humana's Star Ratings Rebound Restores Bonus Payments, Lifting Stock

  • Star Ratings Recovery Restores Bonus Payments CMS upgraded Humana's largest Medicare Advantage contract to 4 stars for 2027, and 95% of members will be in 4-star-plus plans, up from 20%. This restores federal quality bonus payments, boosting future earnings and lifting the stock 15%.

    This is the main new event that directly answers why HUM is moving, with a clear positive impact.

  • Analyst Upgrade on Improved Earnings Outlook Baird upgraded Humana to Outperform with a $596 price target, up from $390, citing confidence in $35-plus of 2028 adjusted EPS. This analyst endorsement reinforces the positive sentiment from the Star Ratings news.

    It shows a direct analyst reaction to the improved fundamentals, supporting the stock's move.

  • Expanded Coverage for Incontinence Device Humana will cover BlueWind Medical's Revi System for urgency urinary incontinence, expanding treatment access for its 11 million Medicare Advantage enrollees. This is a minor positive but shows Humana's role in adopting new technologies.

    It is a new coverage decision that could marginally improve Humana's reputation and member satisfaction.

  • Medicare Advantage Industry Retrenchment Centene is exiting 344 counties and three states for 2027, and Humana plans to exit 57 counties and Minnesota, as premiums are expected to decline 16.5%. This industry-wide pullback reflects ongoing pressure on Medicare Advantage profitability.

    It provides context on the challenging Medicare Advantage environment, a counterweight to the positive Star Ratings news.

Q3 2026
▼2▲1

Humana cuts 2026 profit outlook on star ratings drop

  • Star ratings cut triggers profit outlook reduction Humana lowered its 2026 profit forecast to at least $6.52 per share from $8.36 after fewer Medicare Advantage plans earned four-plus star ratings, reducing federal bonuses. Shares fell about 9% premarket.

    This was the main negative event that drove the stock down during the quarter.

  • Strong Q2 earnings beat and membership growth Q2 adjusted earnings of $7.61 beat estimates by over 20%, with revenue up 26% to $40.9 billion and membership up 20.7%. This shows underlying business strength despite the outlook cut.

    This positive result provided a counterweight to the negative star ratings news.

  • Margin recovery path and expansion offset by headwinds Humana reiterated a path to 3% margins by 2028, with weaker plan exits and Medicaid/home-health expansion. But risks include the end of a $3.6 billion Part D subsidy raising 2027 premiums and 600,000 MA members dropped for 2027.

    This captures the balanced mix of positive strategic progress and negative regulatory/market pressures.

  • Medicare fraud settlement and sector cost pressures A $541.5 million Medicare fraud settlement highlighted upcoding scrutiny, and sector-wide medical cost pressures persist. These add regulatory and financial risks that could weigh on future profits.

    This points to ongoing legal and cost challenges that could affect Humana's financial performance.

September 2026
▼3▲1

Humana cuts 600k MA members, Star Ratings recovery is key catalyst

  • Humana drops 600,000 Medicare Advantage members for 2027 Humana is cutting about 600,000 members from its Medicare Advantage plans next year, its second straight year of big cuts, to protect profit margins as medical costs rise. Fewer members means less premium revenue, which pressures the stock, though it may help margins.

    This is the core new event driving Humana's outlook and was confirmed in this period.

  • Star Ratings recovery targeted as key catalyst Humana aims to return to top-quartile Star Ratings by 2028, which would boost bonus payments and plan economics. Early progress is encouraging, and the October CMS ratings release is the next test. A rebound could support the stock, though shares already trade at a high valuation.

    Star Ratings recovery is a major potential upside driver for Humana's turnaround and margins.

  • Medicare fraud settlement and upcoding scrutiny The Villages Health settled a $541.5 million Medicare fraud case over inflated diagnosis codes. Humana's CenterWell unit is shielded from direct payment, but Humana received inflated payments and is returning overpayments. The case signals heightened government scrutiny on risk-adjustment practices, a regulatory risk for Humana.

    This highlights a regulatory overhang that could affect Humana's payments and reputation.

  • Sector-wide cost pressures and macro headwinds Managed care stocks, including Humana, fell after CVS Health warned of elevated medical costs. Rising oil prices and Treasury yields added to market pressure. These sector-wide concerns weigh on Humana's stock, though they are not specific to the company.

    This explains a broad negative sentiment affecting Humana's price during the period.

▼3▲1

Humana cuts 600k MA members, Star Ratings recovery is key catalyst

  • Humana drops 600,000 Medicare Advantage members for 2027 Humana is cutting about 600,000 members from its Medicare Advantage plans next year, its second straight year of big cuts, to protect profit margins as medical costs rise. Fewer members means less premium revenue, which pressures the stock, though it may help margins.

    This is the core new event driving Humana's outlook and was confirmed in this period.

  • Star Ratings recovery targeted as key catalyst Humana aims to return to top-quartile Star Ratings by 2028, which would boost bonus payments and plan economics. Early progress is encouraging, and the October CMS ratings release is the next test. A rebound could support the stock, though shares already trade at a high valuation.

    Star Ratings recovery is a major potential upside driver for Humana's turnaround and margins.

  • Medicare fraud settlement and upcoding scrutiny The Villages Health settled a $541.5 million Medicare fraud case over inflated diagnosis codes. Humana's CenterWell unit is shielded from direct payment, but Humana received inflated payments and is returning overpayments. The case signals heightened government scrutiny on risk-adjustment practices, a regulatory risk for Humana.

    This highlights a regulatory overhang that could affect Humana's payments and reputation.

  • Sector-wide cost pressures and macro headwinds Managed care stocks, including Humana, fell after CVS Health warned of elevated medical costs. Rising oil prices and Treasury yields added to market pressure. These sector-wide concerns weigh on Humana's stock, though they are not specific to the company.

    This explains a broad negative sentiment affecting Humana's price during the period.

July 2026
▲2▼2

Humana cuts profit outlook on lower star ratings; Q2 beat and growth plans

  • Medicare star rating drop cuts 2026 profit outlook Humana lowered its full-year GAAP earnings target to at least $6.52 per share from $8.36 because fewer plans earned four stars or more, reducing federal quality bonuses. This directly cuts expected profit and is the main reason the stock fell about 9% premarket.

    This is the biggest new negative event and explains the profit outlook cut.

  • Q2 earnings beat on membership and revenue growth Humana reported adjusted earnings of $7.61 per share, beating estimates by over 20%, with revenue up 26% to $40.9 billion and medical membership up 20.7% to 17.9 million. Strong results show the core business is growing, which supports the stock.

    This is a new positive counterweight to the profit outlook cut.

  • End of Medicare Part D subsidy raises 2027 premiums The Trump administration ended a subsidy that gave insurers about $3.6 billion in 2026. Without it, most enrollees will pay more in 2027, and insurers like Humana may see lower government payments and pressure on Part D margins, which is a negative for future profits.

    This is a new regulatory change that affects Humana's future Medicare Part D business.

  • Operational streamlining and growth initiatives Humana is targeting a 3% margin by 2028, exiting weaker Medicare Advantage plans, and expanding Medicaid and home health through a $900 million divestiture and the MaxHealth acquisition. These moves aim to improve long-term profitability and offset star rating issues.

    This shows management's plan to fix margins and grow, which is new and relevant to the big picture.

▲2▼2

Humana cuts profit outlook on lower star ratings; Q2 beat and growth plans

  • Medicare star rating drop cuts 2026 profit outlook Humana lowered its full-year GAAP earnings target to at least $6.52 per share from $8.36 because fewer plans earned four stars or more, reducing federal quality bonuses. This directly cuts expected profit and is the main reason the stock fell about 9% premarket.

    This is the biggest new negative event and explains the profit outlook cut.

  • Q2 earnings beat on membership and revenue growth Humana reported adjusted earnings of $7.61 per share, beating estimates by over 20%, with revenue up 26% to $40.9 billion and medical membership up 20.7% to 17.9 million. Strong results show the core business is growing, which supports the stock.

    This is a new positive counterweight to the profit outlook cut.

  • End of Medicare Part D subsidy raises 2027 premiums The Trump administration ended a subsidy that gave insurers about $3.6 billion in 2026. Without it, most enrollees will pay more in 2027, and insurers like Humana may see lower government payments and pressure on Part D margins, which is a negative for future profits.

    This is a new regulatory change that affects Humana's future Medicare Part D business.

  • Operational streamlining and growth initiatives Humana is targeting a 3% margin by 2028, exiting weaker Medicare Advantage plans, and expanding Medicaid and home health through a $900 million divestiture and the MaxHealth acquisition. These moves aim to improve long-term profitability and offset star rating issues.

    This shows management's plan to fix margins and grow, which is new and relevant to the big picture.

Q2 2026
▲3▼2

Humana wins Medicaid, pushes margin recovery, CenterWell grows

  • Illinois Medicaid win expands members Humana won a statewide Illinois Medicaid contract, adding members across all 102 counties starting January 2027. More members mean more premium revenue, which supports future earnings and makes the stock more attractive.

    New contract directly expands Humana's revenue base.

  • AI gains may be competed away UBS says hospitals may benefit more from AI than insurers because insurers' efficiency gains are easily copied and competed away through pricing. This limits how much Humana can improve margins from AI, a headwind for profit growth.

    Analyst view questions durability of insurer AI margin gains.

  • Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care among major Medicare Advantage insurers, including Humana. This raises regulatory and reputational risk, which could lead to stricter rules or fines, pressuring the stock.

    Regulatory scrutiny can hurt Humana's Medicare Advantage business.

  • Margin recovery plan and strong Q1 Humana beat Q1 earnings estimates and targets insurance margins above 3% by 2028, with disciplined pricing and cost cuts. Strong results and a clear profit plan boost investor confidence, pushing the stock up.

    New earnings and margin targets show improving profitability.

  • CenterWell drives growth beyond insurance CenterWell revenue jumped 19.7% to $6.1 billion, with growth in primary care, home health, and pharmacy. This diversification reduces reliance on insurance and adds a steady profit stream, supporting the stock.

    CenterWell's strong growth is a key new driver of Humana's value.

June 2026
▲3▼2

Humana wins Medicaid, pushes margin recovery, CenterWell grows

  • Illinois Medicaid win expands members Humana won a statewide Illinois Medicaid contract, adding members across all 102 counties starting January 2027. More members mean more premium revenue, which supports future earnings and makes the stock more attractive.

    New contract directly expands Humana's revenue base.

  • AI gains may be competed away UBS says hospitals may benefit more from AI than insurers because insurers' efficiency gains are easily copied and competed away through pricing. This limits how much Humana can improve margins from AI, a headwind for profit growth.

    Analyst view questions durability of insurer AI margin gains.

  • Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care among major Medicare Advantage insurers, including Humana. This raises regulatory and reputational risk, which could lead to stricter rules or fines, pressuring the stock.

    Regulatory scrutiny can hurt Humana's Medicare Advantage business.

  • Margin recovery plan and strong Q1 Humana beat Q1 earnings estimates and targets insurance margins above 3% by 2028, with disciplined pricing and cost cuts. Strong results and a clear profit plan boost investor confidence, pushing the stock up.

    New earnings and margin targets show improving profitability.

  • CenterWell drives growth beyond insurance CenterWell revenue jumped 19.7% to $6.1 billion, with growth in primary care, home health, and pharmacy. This diversification reduces reliance on insurance and adds a steady profit stream, supporting the stock.

    CenterWell's strong growth is a key new driver of Humana's value.

▲3▼2

Humana wins Medicaid, pushes margin recovery, CenterWell grows

  • Illinois Medicaid win expands members Humana won a statewide Illinois Medicaid contract, adding members across all 102 counties starting January 2027. More members mean more premium revenue, which supports future earnings and makes the stock more attractive.

    New contract directly expands Humana's revenue base.

  • AI gains may be competed away UBS says hospitals may benefit more from AI than insurers because insurers' efficiency gains are easily copied and competed away through pricing. This limits how much Humana can improve margins from AI, a headwind for profit growth.

    Analyst view questions durability of insurer AI margin gains.

  • Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care among major Medicare Advantage insurers, including Humana. This raises regulatory and reputational risk, which could lead to stricter rules or fines, pressuring the stock.

    Regulatory scrutiny can hurt Humana's Medicare Advantage business.

  • Margin recovery plan and strong Q1 Humana beat Q1 earnings estimates and targets insurance margins above 3% by 2028, with disciplined pricing and cost cuts. Strong results and a clear profit plan boost investor confidence, pushing the stock up.

    New earnings and margin targets show improving profitability.

  • CenterWell drives growth beyond insurance CenterWell revenue jumped 19.7% to $6.1 billion, with growth in primary care, home health, and pharmacy. This diversification reduces reliance on insurance and adds a steady profit stream, supporting the stock.

    CenterWell's strong growth is a key new driver of Humana's value.

Oscar Health Inc (OSCR)

Q3 2026
▲3▼1

Oscar Health raised guidance, launched AI marketplace, but risks remain

  • Record first half and raised 2026 guidance Oscar Health reported a record first half and raised its 2026 operating profit guidance by $250 million to $500–$700 million, with membership up 46% to 2.96 million despite a weaker ACA market.

    This is a major positive development that directly boosted investor confidence and the stock price.

  • Investor day: doubled EPS, 2027 target, AI launch At its investor day, Oscar lifted 2026 guidance again, doubled EPS expectations, set a $4 EPS target for 2027, and launched Lucy, an AI marketplace connecting ~70 carriers.

    These forward-looking initiatives and targets signal strong future growth and innovation.

  • Analyst upgrades on surging estimates Analysts upgraded the stock on surging estimates, reflecting increased optimism about Oscar's financial trajectory.

    Analyst upgrades often drive positive price momentum and validate the company's outlook.

  • Persistent risks: costs, CMS checks, valuation However, risks persist: guidance still implies a large second-half operating loss, outpatient and industry medical costs remain elevated, CMS eligibility checks could cause enrollment losses, and some fair-value estimates sit below the current price.

    These factors could pressure the stock and temper the positive outlook.

August 2026
▲3▼1

Oscar raises guidance, targets $4 EPS, launches Lucy marketplace

  • Oscar raises 2026 guidance and targets $4 EPS by 2027 At its investor day, Oscar raised 2026 earnings guidance by $100 million, doubled this year's EPS expectation, and set a $4 EPS target for 2027. It credited favorable medical cost trends and a better medical loss ratio. Higher expected profits make the stock more attractive.

    This is the biggest new fundamental catalyst, directly raising future earnings expectations.

  • New Lucy AI marketplace opens a new growth channel Oscar launched Lucy, an AI-driven marketplace connecting about 70 carriers with consumers and brokers for ACA and supplemental plans. It also sees a chance to move employer coverage into the ACA. A new business line could add revenue and profit beyond its own insurance plans.

    This is a new business initiative that could expand Oscar's addressable market and long-term growth.

  • Analyst upgrade on surging earnings estimates Oscar was upgraded to Zacks Rank #1 Strong Buy after its consensus earnings estimate jumped 290% in three months. The upgrade reflects the improved profit outlook and could draw more institutional buyers, though it is a backward-looking signal based on estimate revisions.

    It shows the market's earnings expectations have risen sharply, which can support the stock price.

  • Industry medical costs stay high, pressuring managed care CVS Health said at a conference that medical costs remain elevated, and managed care stocks including Oscar fell. High medical costs can squeeze insurers' profits if they pay out more in claims. This is a real counterweight to Oscar's upbeat guidance.

    It is the main negative force this period and a risk to Oscar's cost outlook.

Latest
▲3▼1

Oscar raises guidance, targets $4 EPS, launches Lucy marketplace

  • Oscar raises 2026 guidance and targets $4 EPS by 2027 At its investor day, Oscar raised 2026 earnings guidance by $100 million, doubled this year's EPS expectation, and set a $4 EPS target for 2027. It credited favorable medical cost trends and a better medical loss ratio. Higher expected profits make the stock more attractive.

    This is the biggest new fundamental catalyst, directly raising future earnings expectations.

  • New Lucy AI marketplace opens a new growth channel Oscar launched Lucy, an AI-driven marketplace connecting about 70 carriers with consumers and brokers for ACA and supplemental plans. It also sees a chance to move employer coverage into the ACA. A new business line could add revenue and profit beyond its own insurance plans.

    This is a new business initiative that could expand Oscar's addressable market and long-term growth.

  • Analyst upgrade on surging earnings estimates Oscar was upgraded to Zacks Rank #1 Strong Buy after its consensus earnings estimate jumped 290% in three months. The upgrade reflects the improved profit outlook and could draw more institutional buyers, though it is a backward-looking signal based on estimate revisions.

    It shows the market's earnings expectations have risen sharply, which can support the stock price.

  • Industry medical costs stay high, pressuring managed care CVS Health said at a conference that medical costs remain elevated, and managed care stocks including Oscar fell. High medical costs can squeeze insurers' profits if they pay out more in claims. This is a real counterweight to Oscar's upbeat guidance.

    It is the main negative force this period and a risk to Oscar's cost outlook.

July 2026
▲2▼1

Oscar's record first half and raised guidance drive gains, but cost and policy risks linger

  • Record first-half profit and raised 2026 outlook Oscar reported record first-half earnings and lifted its full-year operating profit target by $250 million to $500–$700 million. That tells investors the core business is more profitable than expected, which supports a higher stock price.

    This is the main new event that changed the company's profit outlook and directly pushes the stock up.

  • Second-half loss implied and cost worries The raised full-year guidance still implies a second-half operating loss of roughly $393–$593 million. Analysts also flagged rising outpatient costs and possible enrollment losses from CMS eligibility checks, which could pressure future profits and the stock.

    This is the key counterweight that explains why the stock fell after the guidance hike and why future gains are not guaranteed.

  • Membership surges 46% despite weaker ACA market Oscar ended the second quarter with 2.96 million members, up 46% from a year earlier, even as overall ACA enrollment weakened after enhanced subsidies expired. That suggests Oscar is taking market share, which can drive future revenue and profit.

    This is a new update on membership growth, a core driver of Oscar's revenue and long-term value.

  • Analysts lift estimates but see limited upside After the strong first half, analysts raised earnings estimates and pointed to a low PEG ratio of 0.6. However, some fair-value estimates sit below the current price, and risks remain from subsidy shifts and rising medical costs, so the stock's path depends on sustained margin improvement.

    This shows how the market is repricing Oscar after the results, balancing optimism with valuation and policy risks.

▲2▼1

Oscar's record first half and raised guidance drive gains, but cost and policy risks linger

  • Record first-half profit and raised 2026 outlook Oscar reported record first-half earnings and lifted its full-year operating profit target by $250 million to $500–$700 million. That tells investors the core business is more profitable than expected, which supports a higher stock price.

    This is the main new event that changed the company's profit outlook and directly pushes the stock up.

  • Second-half loss implied and cost worries The raised full-year guidance still implies a second-half operating loss of roughly $393–$593 million. Analysts also flagged rising outpatient costs and possible enrollment losses from CMS eligibility checks, which could pressure future profits and the stock.

    This is the key counterweight that explains why the stock fell after the guidance hike and why future gains are not guaranteed.

  • Membership surges 46% despite weaker ACA market Oscar ended the second quarter with 2.96 million members, up 46% from a year earlier, even as overall ACA enrollment weakened after enhanced subsidies expired. That suggests Oscar is taking market share, which can drive future revenue and profit.

    This is a new update on membership growth, a core driver of Oscar's revenue and long-term value.

  • Analysts lift estimates but see limited upside After the strong first half, analysts raised earnings estimates and pointed to a low PEG ratio of 0.6. However, some fair-value estimates sit below the current price, and risks remain from subsidy shifts and rising medical costs, so the stock's path depends on sustained margin improvement.

    This shows how the market is repricing Oscar after the results, balancing optimism with valuation and policy risks.